康美药业财务造假案例分析

Case Analysis of Financial Fraud of Kangmei Pharmaceutical

上市公司追求利润最大化原则,在面临证券市场60万顶额处罚的环境下,企业财务舞弊现象频发,侵害了投资者的利益。作者从财务造假动机、粉饰手法、预警信号三个层面分析上市公司财务舞弊行为,发现康美药业一方面通过关联交易谋求了更高利益,另一方面康美药业提前确认营业收入、推迟确认成本费用进行舞弊,并通过改变会计处理方式虚增了高额的净利润,披露了虚假的信息,造成了价值投资者的损失。本文从公司、外部监管、审计这三个层面针对上市公司舞弊行为提出相应的策略,以求降低舞弊的可能性,保护投资者权益。

Listed companies pursue the principle of profit maximization.In the face of a maximum penalty of 600000 yuan in the securities market,corporate financial fraud occurs frequently,infringing the interests of investors.The author analyzed the financial fraud behavior of listed companies from three aspects of financial fraud motivation,whitewashing method and warning signal,and found that on the one hand,Kangmei Pharmaceutical sought higher benefits through related party transactions,on the other hand,Kangmei Pharmaceutical confirmed its operating income in advance,delayed the confirmation of costs and expenses,and fraudulently increased its high net profit by changing the accounting treatment method,disclosed false information,and caused losses to value investors.This paper puts forward corresponding strategies for listed companies'fraud from three levels,namely,company,external supervision and audit,in order to reduce the possibility of fraud and protect the rights and interests of investors.